PRECLINICAL EFFICACY OF DIRECT AMPK ACTIVATION WITH A NOVEL SMALL MOLECULE-PXL770-FOR THE TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE

Dagorn PG, Buchholz B, Bange H, Blockken L, Moller DE, Hallakou-Bozec S (2022)

Publication Type: Conference contribution

Publication year: 2022

Journal

Nephrology Dialysis Transplantation Oxford University Press (OUP): Policy B

Publisher: OXFORD UNIV PRESS

City/Town: OXFORD

Pages Range: I9-I9

Conference Proceedings Title: NEPHROLOGY DIALYSIS TRANSPLANTATION

DOI: 10.1093/ndt/gfac061.014

Authors with CRIS profile

Björn Buchholz Medizinische Fakultät

Involved external institutions

Crown Bioscience NL Netherlands (NL) Poxel SA FR France (FR) InnoSer België BE Belgium (BE)

How to cite

APA:

Dagorn, P.G., Buchholz, B., Bange, H., Blockken, L., Moller, D.E., & Hallakou-Bozec, S. (2022). PRECLINICAL EFFICACY OF DIRECT AMPK ACTIVATION WITH A NOVEL SMALL MOLECULE-PXL770-FOR THE TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE. In NEPHROLOGY DIALYSIS TRANSPLANTATION (pp. I9-I9). OXFORD: OXFORD UNIV PRESS.

MLA:

Dagorn, Pascale Gluais, et al. "PRECLINICAL EFFICACY OF DIRECT AMPK ACTIVATION WITH A NOVEL SMALL MOLECULE-PXL770-FOR THE TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE." Proceedings of the NEPHROLOGY DIALYSIS TRANSPLANTATION OXFORD: OXFORD UNIV PRESS, 2022. I9-I9.

BibTeX: Download